James, Aaron W.
Shen, Jia
Zhang, Xinli
Asatrian, Greg
Goyal, Raghav
Kwak, Jin H.
Jiang, Lin
Bengs, Benjamin
Culiat, Cymbeline T.
Turner, A. Simon
Seim III, Howard B.
Wu, Benjamin M.
Lyons, Karen
Adams, John S.
Ting, Kang
Soo, Chia
Article History
Received: 16 February 2015
Accepted: 28 April 2015
First Online: 17 June 2015
Change Date: 13 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-20933-x
Change Details: .
Competing interests
: X.Z., B.W., K.T. and C.S. are inventors of NELL-1-related patents. X.Z., B.W., K.T. and C.S. are founders and/or board members of Bone Biologics Inc., which sublicenses NELL-1 patents from the UC Regents, and also hold equity in the company. C.T.C. is an inventor of NELL-1-related patents filed from ORNL and is a founder of NellOne Therapeutics Inc., which licenses NELL-1-related patent applications from ORNL. The remaining authors declare no competing financial interests.